SCHEMBL21786598

SCHEMBL21786598

Cn1cc(-c2ccc(OCc3ccc(Cl)cc3)cn2)c(C(F)(F)F)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.41
PDE10A Q9Y233 1/20 0.39
FGFR1 P11362 1/20 0.39
FGFR2 P21802 1/20 0.39
FGFR3 P22607 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MAOB P27338 6/20 0.37
APP P05067 1/20 0.37
BRD4 O60885 1/20 0.37
CREBBP Q92793 1/20 0.37
CYP4F2 P78329 2/20 0.37
CYP4A11 Q02928 2/20 0.37
GAA P10253 1/20 0.37
ALKBH1 Q13686 1/20 0.36
MAOA P21397 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21786421 0.84 LMNA (0.41) LMNAPOLBPDE10AFGFR1FGFR2
SCHEMBL19319899 0.83 AR (0.41) SMN1; SMN2MAOBAPPCYP4F2CYP4A11
SCHEMBL21786422 0.82 LMNA (0.41) LMNAPOLBCYP1A2CYP2C9CYP2C19
SCHEMBL21786601 0.81 MAOB (0.46) LMNAPOLBCYP1A2CYP2C9CYP2C19
SCHEMBL19319901 0.81 LMNA (0.39) LMNAPOLBCYP1A2CYP2C9CYP2C19
SCHEMBL21786599 0.79 LMNA (0.47) LMNAPOLBFGFR1FGFR2FGFR3
SCHEMBL21786419 0.79 MAOB (0.42) LMNAPOLBPDE10ACYP1A2CYP2C9
SCHEMBL21786603 0.78 POLB (0.40) LMNAPOLBSMN1; SMN2MAOBGAA
SCHEMBL19319875 0.76 PTGS1 (0.42) CYP1A2CYP2C9CYP2C19SMN1; SMN2MAOB
SCHEMBL21051429 0.74 BRD4 (0.45) LMNAPOLBPDE10AFGFR1FGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3426636-B1 SPECIFIC 2-(4-(PHENOXY)-1H-PYRAZOL-3-YL)PHENOL DERIVATIVES AS INHIBITORS OF C-MYC/DNA BINDING ACTIVITY FOR TREATING CANCER UNIV NORTHWESTERN (US) 2021-12-29 EP disclosed
US-20210395206-A1 SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS NORTHWESTERN UNIVERSITY 2021-12-23 US disclosed
US-11142504-B2 Substituted heterocycles as c-MYC targeting agents NORTHWESTERN UNIVERSITY (US) 2021-10-12 US disclosed
US-20200392116-A1 SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS NORTHWESTERN UNIVERSITY (US) 2020-12-17 US disclosed
WO-2020046382-A1 SUBSTITUTED HETEROCYCLES AS C-MYC TARGETING AGENTS NORTHWESTERN UNIVERSITY (US) 2020-03-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200392116-A1 SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS MYC, MYCBP, MYCBP2 LMNA 3025/4885POLB 2895/4885PDE10A 4189/4885
US-20210395206-A1 SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS MYC, MYCBP, MYCBP2 LMNA 3025/4885POLB 2895/4885PDE10A 4189/4885
US-11142504-B2 Substituted heterocycles as c-MYC targeting agents MYC, MYCBP, MYCBP2 LMNA 3025/4885POLB 2895/4885PDE10A 4189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.